Pfizer Inc. News
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena, and Braftovi brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
see morePfizer Inc. Market News
9d
Impact of FDA Approvals and Analyst Ratings on Pfizer's Stock Activity
- Pfizer's stock reacts to recent FDA approvals and analyst upgrades.
16d
Pfizer's Stock Reacts to FDA Approval of PADCEV-Keytruda Combination for Bladder Cancer
Pfizer's stock rises following FDA approval of PADCEV-Keytruda regimen.
23d
Pfizer's Stock Reacts to FDA Approvals and Leadership Changes
Pfizer's stock experiences fluctuations amid FDA approvals and CFO transition.
29d
Pfizer's Stock Performance Amid Recent Developments in the Biopharmaceutical Sector
Analyzing Pfizer's stock fluctuations in light of recent industry events.
05 May at 14:40
Pfizer Q1 Strength Fuels Oncology, Patent Wins Now
Pfizer’s latest quarterly report and corporate moves this week — strong Q1 results, strategic asset sales, patent settlements and ASCO data plans — are reshaping near-term investor expectations for PFE in the S&P 500. Concrete regulatory and pipeline updates reduce risk while dividend payout concerns temper sentiment.
24 Mar at 14:44
Pfizer PFE: Week Review — No New Catalysts Now Q2!
This week brought no new, stock-moving developments for Pfizer (PFE). Investors should watch the upcoming VESPER-3 obesity readout (June 6, 2026) and the YaoPharma GLP‑1 collaboration (YP05002) as the next meaningful catalysts; near-term trading is likely to be driven by macro, dividend appeal, and positioning within the S&P 500.
17 Mar at 14:38
Pfizer's $0.43 Dividend & Matrix‑M Deal
Pfizer reinforced shareholder returns with a $0.43 quarterly dividend while striking a strategic license with Novavax for the Matrix‑M adjuvant. These concrete moves — dividend continuity and a deal with explicit financial terms — materially affect PFE’s near‑term investor narrative and long‑term vaccine strategy.